{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T13:10:47Z","timestamp":1777813847833,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21-AI115207"],"award-info":[{"award-number":["R21-AI115207"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI095690"],"award-info":[{"award-number":["R01-AI095690"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI007151"],"award-info":[{"award-number":["T32-AI007151"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56-AI44667"],"award-info":[{"award-number":["R56-AI44667"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI50410"],"award-info":[{"award-number":["P30 AI50410"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011072","name":"Center for AIDS Research, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","award":["P30 CA16068"],"award-info":[{"award-number":["P30 CA16068"]}],"id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.antiviral.2018.07.024","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T12:52:12Z","timestamp":1533300732000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus"],"prefix":"10.1016","volume":"158","author":[{"given":"Shuntai","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3035-346X","authenticated-orcid":false,"given":"Sara E.","family":"Williford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-5087","authenticated-orcid":false,"given":"David R.","family":"McGivern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina L.","family":"Burch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Benzine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Asante-Appiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita Y.M.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Swanstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley M.","family":"Lemon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.07.024_bib1","author":"AASLD-IDSA"},{"key":"10.1016\/j.antiviral.2018.07.024_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3851\/IMP3056","article-title":"Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening","volume":"21","author":"Barnard","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.07.024_bib3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.024_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hep.510300137","article-title":"An infectious molecular clone of a Japanese genotype 1b hepatitis C virus","volume":"30","author":"Beard","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006343","article-title":"NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains","volume":"13","author":"Benzine","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.07.024_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2014.07.019","article-title":"Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication","volume":"147","author":"Berger","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/j.gastro.2016.11.047","article-title":"Daclatasvir prevents hepatitis C virus infectivity by blocking transfer of the viral genome to assembly sites","volume":"152","author":"Boson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2105-5-113","article-title":"MUSCLE: a multiple sequence alignment method with reduced time and space complexity","volume":"5","author":"Edgar","year":"2004","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.antiviral.2018.07.024_bib9","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.07.024_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.07.024_bib11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib12","first-page":"1","article-title":"Clinically relevant HCV drug resistance mutations","volume":"14","author":"HCV Drug Development Advisory Group","year":"2012","journal-title":"Ann. Forum Collab HIV Res."},{"key":"10.1016\/j.antiviral.2018.07.024_bib13","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.3390\/v6114227","article-title":"Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding","volume":"6","author":"Issur","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.07.024_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543776.2017.1272573","article-title":"Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)","volume":"27","author":"Ivanenkov","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.antiviral.2018.07.024_bib15","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1128\/AAC.03466-14","article-title":"Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV\/HIV coinfection","volume":"58","author":"Jabara","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.024_bib16","doi-asserted-by":"crossref","first-page":"20166","DOI":"10.1073\/pnas.1110064108","article-title":"Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID","volume":"108","author":"Jabara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.07.024_bib17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1089\/aid.2014.0031","article-title":"Primer ID informs next-generation sequencing platforms and reveals preexisting drug resistance mutations in the HIV-1 reverse transcriptase coding domain","volume":"31","author":"Keys","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2018.07.024_bib18","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1128\/jvi.68.11.7467-7481.1994","article-title":"Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences","volume":"68","author":"Korber","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.024_bib19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pro.2456","article-title":"The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors","volume":"23","author":"Lambert","year":"2014","journal-title":"Protein Sci."},{"key":"10.1016\/j.antiviral.2018.07.024_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.07.024_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAI.0000000000001187","article-title":"Quantification of the latent HIV-1 reservoir using ultra deep sequencing and primer ID in a viral outgrowth assay","volume":"74","author":"Lee","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.07.024_bib22","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.024_bib23","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib24","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1073\/pnas.1416266112","article-title":"Functionally conserved architecture of hepatitis C virus RNA genomes","volume":"112","author":"Mauger","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.07.024_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"McGivern","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1099\/jgv.0.000009","article-title":"Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!","volume":"96","author":"Ross-Thriepland","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.07.024_bib27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.07.024_bib29","first-page":"512","article-title":"Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees","volume":"10","author":"Tamura","year":"1993","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.antiviral.2018.07.024_bib30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nature03580","article-title":"Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase","volume":"435","author":"Tellinghuisen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.07.024_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nm.3610","article-title":"Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation","volume":"20","author":"Yamane","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.07.024_bib32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1073\/pnas.0510727103","article-title":"Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells","volume":"103","author":"Yi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.antiviral.2018.07.024_bib33","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.07.024_bib34","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1128\/JVI.00441-16","article-title":"Deep sequencing of the HIV-1 env gene reveals discrete X4 lineages and linkage disequilibrium between X4 and R5 viruses in the V1\/V2 and V3 variable regions","volume":"90","author":"Zhou","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.024_bib35","doi-asserted-by":"crossref","first-page":"8540","DOI":"10.1128\/JVI.00522-15","article-title":"Primer ID validates template sampling depth and greatly reduces the error rate of next-generation sequencing of HIV-1 genomic RNA populations","volume":"89","author":"Zhou","year":"2015","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218302626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218302626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:10:57Z","timestamp":1777497057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218302626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"alternative-id":["S0166354218302626"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.024","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}